David Walton
Directeur Général chez T1D Exchange
Profil
David Walton is currently the Chief Executive Officer & Director at T1D Exchange.
Previously, he worked as the Director of Global Strategic Marketing at Johnson & Johnson, the Chief Commercial Officer at AgaMatrix, Inc., and the Vice President of Marketing & Commercial Development at Echo Therapeutics, Inc. Mr. Walton completed his undergraduate degree at Princeton University and holds an MBA from The Wharton School of the University of Pennsylvania.
Postes actifs de David Walton
| Sociétés | Poste | Début |
|---|---|---|
T1D Exchange
 T1D Exchange Pharmaceuticals: MajorHealth Technology T1D Exchange is a nonprofit organization that was established in 2010 with initial and ongoing support from the Leona M. and Harry B. Helmsley Charitable Trust. T1D Exchange is based in Boston, MA. The non-profit company is dedicated to improving outcomes for the entire T1D population through real-world evidence and clinical data collection and analysis. T1D Exchange is a leading provider of real-world evidence, identifying gaps in data and redefining best practices to improve the lives of those living with T1D. The company actively supports quality improvement and innovation through its quality improvement collaborative, patient registry, and data-oriented research services. David Walton has been the CEO of the company since 2018. | Directeur Général | 01/04/2019 |
Anciens postes connus de David Walton
| Sociétés | Poste | Fin |
|---|---|---|
AgaMatrix, Inc.
 AgaMatrix, Inc. Electronic Equipment/InstrumentsElectronic Technology AgaMatrix, Inc. develops and manufactures medical devices. It offers next generation blood glucose monitoring products for the diabetes market. The firm’s products include iBGStar Diabetes Manager and Zero-Click software. The company was founded by Sridhar G. Iyengar, Ian S. Harding and Sonny X. Vu in 2001 and is headquartered in Salem, NH. | Corporate Officer/Principal | - |
| JOHNSON & JOHNSON | Sales & Marketing | - |
| ECHO THERAPEUTICS, INC. | Corporate Officer/Principal | 15/06/2012 |
Formation de David Walton
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| Princeton University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| Entreprise privées | 3 |
|---|---|
Echo Therapeutics, Inc.
 Echo Therapeutics, Inc. Medical SpecialtiesHealth Technology Echo Therapeutics, Inc. is a medical device company, which engages in the development of non-invasive, and wireless continuous glucose monitoring system for use in the diabetes outpatient market. It offers needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose and delivery of topical pharmaceuticals. The company was founded in 1989 and is headquartered in Iselin, NJ. | Health Technology |
AgaMatrix, Inc.
AgaMatrix, Inc. Electronic Equipment/InstrumentsElectronic Technology AgaMatrix, Inc. develops and manufactures medical devices. It offers next generation blood glucose monitoring products for the diabetes market. The firm’s products include iBGStar Diabetes Manager and Zero-Click software. The company was founded by Sridhar G. Iyengar, Ian S. Harding and Sonny X. Vu in 2001 and is headquartered in Salem, NH. | Electronic Technology |
T1D Exchange
T1D Exchange Pharmaceuticals: MajorHealth Technology T1D Exchange is a nonprofit organization that was established in 2010 with initial and ongoing support from the Leona M. and Harry B. Helmsley Charitable Trust. T1D Exchange is based in Boston, MA. The non-profit company is dedicated to improving outcomes for the entire T1D population through real-world evidence and clinical data collection and analysis. T1D Exchange is a leading provider of real-world evidence, identifying gaps in data and redefining best practices to improve the lives of those living with T1D. The company actively supports quality improvement and innovation through its quality improvement collaborative, patient registry, and data-oriented research services. David Walton has been the CEO of the company since 2018. | Health Technology |